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Abstract 
Three novel NY-ESO-1 CD4 T cell epitopes were identified using PBMC ob-
tained from patients who were vaccinated with a complex of cholesterol-bearing 
hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1).  The 
restriction molecules were determined by antibody blocking and using various 
EBV-B cells with different HLA alleles as APC for presenting peptides for CD4 T 
cells.  The minimal epitope peptides were determined using various N- and 
C-termini truncated peptides deduced from 18-mer overlapping peptides origi-
nally identified for recognition.  Those epitopes were DRB1*0901-restricted 
NY-ESO-1 87-100, DQB1*0401- restricted NY-ESO-1 95-107 and DRB1*0803- 
restricted NY-ESO-1 124-134.  CD4 T cells used for determining those epitope 
peptides recognized EBV-B cells or DC that were treated with recombinant 
NY-ESO-1 protein or NY-ESO-1-expressing tumor cell lysate, suggesting that 
the epitope peptides are naturally processed.  Those CD4 T cells showed a 
cytokine profile with Th1 characteristics.  Furthermore, NY-ESO-1 87-100 pep-
tide/HLA-DRB1*0901 tetramer staining was observed.  Multiple Th1-type CD4 
T cell responses are beneficial for inducing effective anti-tumor responses after 
NY-ESO-1 protein vaccination.  
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1. Introduction 
The NY-ESO-1 antigen was initially identified in esophageal cancer by SEREX 
and is in the category of cancer/testis (CT) antigens [1-3].  Its expression is re-
stricted to germ cells in the testis in normal adult tissues, but is also observed in 
various types of cancer tissue at different frequencies [4].  A characteristic of 
the NY-ESO-1 antigen is its extremely high immunogenicity.  Patients with 
NY-ESO-1-expressing tumors frequently show a spontaneous immune response 
to the NY-ESO-1 antigen.  An antibody response against the NY-ESO-1 antigen 
was frequently observed in patients with NY-ESO-1-expressing tumors [5, 6].  
Most patients who showed an antibody response also showed CD4 and CD8 T 
cell responses [7, 8].  Such strong immunogenicity makes the NY-ESO-1 anti-
gen a very promising candidate target molecule for a cancer vaccine. 
Several clinical trials using various preparations of NY-ESO-1 protein vaccine 
have been reported [3, 9].  The recombinant NY-ESO-1 protein was adminis-
tered with ISCOMATRIX [10], cholesterol-bearing hydrophobized pullulan (CHP) 
[11], CpG in Montanide [12], imiquimod [13] or as recombinant vaccinia/fowlpox 
NY-ESO-1 [14].  Analyses of immune responses in patients vaccinated with the 
NY-ESO-1 protein showed that integrated immune responses of antibodies, CD4 
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and CD8 T cells were induced after vaccination.   
In this study, we analyzed CD4 T cell responses against NY-ESO-1 in PBMC 
from 3 patients who were vaccinated with a complex of CHP and NY-ESO-1 
protein (CHP-NY-ESO-1) in our clinical trial [11, 15-17] and determined 3 novel 
NY-ESO-1 CD4 T cell epitopes.  These epitopes were NY-ESO-1 87-100 bound 
to DRB1*0901, NY-ESO-1 95-107 bound to DQB1*0401 and NY-ESO-1 124-134 
bound to DRB1*0803.  CD4 T cells used for determining these epitope peptides 
recognized EBV-B cells or DC that were treated with recombinant NY-ESO-1 
protein or NY-ESO-1-expressing tumor cell lysate, suggesting that the epitope 
peptides are naturally processed.  These CD4 T cells showed a cytokine profile 
with Th1 characteristics. 
 
 
2. Materials and Methods 
2.1. Patients 
Patients listed in Fig. 1 were vaccinated with CHP-NY-ESO-1 in our clinical trial 
reported elsewhere [11, 15-17].  Patients in the E- series were esophageal 
cancer patients.  Patients in the P- series were prostate cancer patients.  M-1 
 - 6 - 
was a malignant melanoma patient.   
 
2.2. Blood samples 
Peripheral blood samples were drawn from vaccinated patients after informed 
consent was obtained.  Peripheral blood mononuclear cells (PBMC) were iso-
lated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich, 
St. Louis, MO).  CD4 T cells, CD8 T cells, CD14+ cells and CD19+ cells were 
purified from PBMC using CD4, CD8, CD14 and CD19 microbeads, respectively, 
using a large scale column and a magnetic device (Miltenyi Biotec, Auburn, CA).  
The residual cells were used as antigen-presenting cells (APC).  The cells were 
stored in liquid N2 until use.  HLA typing of PBMC was performed by a se-
quence-specific oligo-nucleotide probe and sequence-specific priming of ge-
nomic DNA using standard procedures. 
 
2.3. Antibodies 
Anti-human CD4, anti-human CD8, anti-HLA class I, anti-HLA class II, anti-DQ 
and anti-DR monoclonal antibodies (mAbs) were purchased from BD Bioscience 
(San Jose, CA).  Anti-DP mAb was purchased from Santa Cruz (Santa Cruz, 
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CA).  These monoclonal antibodies were used for an antibody blocking test in 
ELISA.  Anti-human IFNγ mAb (1-DIK) was obtained from Mabtech (Stockholm, 
Sweden).  Polyclonal rabbit anti-human IFNγ serum was obtained by immu-
nizing a rabbit with recombinant human IFNγ protein.  Horseradish peroxidase 
conjugated goat anti-rabbit IgG was purchased from MBL (Nagoya, Japan).   
 
2.4. Cell lines 
Epstein-Barr virus-transformed B cells (EBV-B) were generated from CD19+ pe-
ripheral blood B cells using the culture supernatant from EBV-producing B95-8 
cells.  OU-LC-KI and OU-LC-OK were lung adenocarcinoma cell lines estab-
lished in our laboratory.  These cell lines were kept in tissue culture by serial 
passage and in liquid N2. 
 
2.5. Peptides 
The following 28 18-mer overlapping peptides spanning the NY-ESO-1 protein 
were synthesized: 18.1 (1-18), 18.2 (7-24), 18.3 (13-30), 18.4 (19-36), 18.5 
(25-42), 18.6 (31-48), 18.7 (37-54), 18.8 (43-60), 18.9 (49-66), 18.10 (55-72), 
18.11 (61-78), 18.12 (67-84), 18.13 (73-90), 18.14 (79-96), 18.15 (85-102), 
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18.16 (91-108), 18.17 (97-114), 18.18 (103-120), 18.19 (109-126), 18.20 
(115-132), 18.21 (121-138), 18.22 (127-144), 18.23 (133-150), 18.24 (139-156), 
18.25 (145-162), 18.26 (149-166), 18.27 (153-170) and 18.28 (156-173).   A 
30-mer NY-ESO-1 151-180 peptide was also synthesized.  These peptides 
were synthesized using standard solid-phase methods based on 
N-(9-fluorenyl)-methoxycarbonyl (Fmoc) chemistry on a Multiple Peptide Syn-
thesizer (AMS422, ABIMED, Langenfeld, Germany) at Okayama University 
(Okayama, Japan). 
 
2.6. Recombinant proteins  
Recombinant NY-ESO-1 [18] and RL-Akt [19] proteins were prepared as de-
scribed previously.  cDNAs for NY-ESO-1 and RL-Akt were cloned into Sph 
I/Sal I and Bam HI/Sph I sites of the pQE30 vector (Qiagen Science, Valencia, 
CA), respectively.  N-His tagged protein was purified by nickel-ion affinity 
chromatography under denaturing conditions.  
 
2.7. Total RNA isolation and cDNA synthesis 
Total RNA was isolated from cell pellets using an RNeasy Mini Kit (QIAGEN, 
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Hilden, Germany).  Isolated RNA (2 µg) was reverse transcribed into sin-
gle-stranded cDNA using Moloney murine leukemia virus reverse transcriptase 
(Ready-To-Go You-Prime First-Strand Beads, GE Healthcare, Little Chalfont, 
UK) and oligo (dT)15 as a primer.  cDNA was tested for integrity by amplification 
of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. 
 
2.8. Reverse transcription (RT)-PCR analysis 
To amplify the NY-ESO-1 cDNA segment, primers specific for NY-ESO-1 were 
designed as described previously [20].  Primers for RT-PCR were: NY-ESO-1 
5'-AGTTCTACCTCGCCATGCCT-3' (forward), 
5'-TCCTCCTCCAGCGACAAACAA-3' (reverse), GAPDH 
5'-ACCACAGTCCATGCCATCAC-3' (forward), 
5'-TCCACCACCCTGTTGCTGTA-3' (reverse).  The amplification program for 
NY-ESO-1 was 1 min at 94°C, 1 min at 60°C, and 1.5 min at 72°C for 35 cycles 
after denaturing at 94°C for 1 min.  These cycles were followed by a 10 min 
elongation step at 72°C.  The amplification program for GAPDH was 1 min at 
94°C, 1 min at 66°C, and 1.5 min at 72°C for 30 cycles after denaturing at 94°C 
for 1 min. These cycles were followed by a 10 min elongation step at 72°C. The 
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PCR products were analyzed on a 1.3% agarose gel.   
 
2.9. Preparation of monocyte-derived dendritic cells (DC) 
CD14+ cells from PBMC were cultured in RPMI medium supplemented with 5% 
pooled human serum, 10 ng/ml IL-4 and 10 ng/ml granulocyte macrophage co-
lony-stimulating factor (GM-CSF) for 10 days at 37°C in a 5% CO2 atmospher.   
 
2.10. Preparation of tumor cell lysate 
Tumor cells (1 x 107) were subjected to five cycles of rapid freezing in liquid N2 
followed by thawing in a water bath at 37°C.   
 
2.11. In vitro stimulation of CD4 T cells  
Frozen cells were thawed and re-suspended in AIM-V medium (Invitrogen, 
Carlsbad, CA) supplemented with 5% pooled human serum (CM), and kept at 
37°C in a 5% CO2 atmosphere for 2 hrs.  CD4 T cells (2 x 10
6) were stimulated 
with 28 18-mer overlapping peptides and a 30-mer C-terminal peptide (OLPs) (1 
µg/ml for each peptide) spanning the entire NY-ESO-1 using irradiated (40 Gy), 
autologous CD4- and CD8-depleted PBMC (2 x 106) as antigen-presenting cells 
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(APC) in 2 ml of CM supplemented with 20 units/ml rIL-2 (Takeda Chemical In-
dustries, Osaka, Japan) and 10 ng/ml rIL-7 (Peprotech, London, UK) in a 24-well 
culture plate at 37°C in a 5% CO2 atmosphere for 12 days.  For the second 
stimulation, 1 x 106 instead of 2 x 106 responder cells were used in the culture 
described above.                                                                                                                                                                                                          
 
2.12. IFNγ secretion assay  
Responder CD4 T cells (1 x 105) were stimulated for 4 hrs with pa-
ra-formaldehyde (PFA) (Wako, Osaka, Japan) (0.2%)-treated autologous EBV-B 
cells (1 x 105) pre-pulsed with the peptides for 30 min.  The cells were then 
washed and suspended in 100 μl of RPMI medium, and treated with bi-specific 
CD45 and the IFNγ antibody (Miltenyi Biotec) (2 μl) for 5 min on ice.  The cells 
were then diluted in AIM-V medium (1-10 ml) and placed on a slowly rotating 
device (Miltenyi Biotec) to allow IFNγ secretion at 37°C in a 5% CO2 atmosphere.  
After incubation for 50 min, the cells were washed with cold buffer and treated 
with PE-conjugated anti-IFNγ, and FITC-conjugated anti-CD4 mAb.  After in-
cubation for 10 min at 4°C, the cells were washed and analyzed by FACS Cali-
bur (Becton Dickinson).   
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2.13. Peptide pulse and treatment with protein or tumor lysate on APC 
EBV-B cells were pulsed with peptides for 3 hrs or treated with protein for 24 hrs 
in 24-well culture plate at 37°C in a 5% CO2 atmosphere.  The cells were then 
fixed by PFA (0.2%) and used for stimulating CD4 T cells in the assay.  EBV-B 
cells or DC pretreated with tumor cell lysate (equivalent to 1 x 107 cells) for 24 
hrs were also used as APC for stimulation.   
 
2.14. ELISA  
Supernatants from cultures of CD4 T cells (1 x 104) stimulated with EBV-B cells 
(1 x 104) pre-pulsed with peptide or pretreated with protein, or with EBV-B cells 
or DC pretreated with cell lysate were collected and the amounts of IFNγ, TNFα, 
IL-4 or IL-10 were estimated by sandwich ELISA.  For antibody blocking, each 
purified mAb (5 μg/ml) was added to the assay culture.    
 
2.15. Flow cytometry 
EBV-B cells were cultured with rNY-ESO-1 protein, CHP-NY-ESO-1 or 
CHP-MAGE at 10 μg/ml of a protein concentration in a 24-well culture plate for 
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18 hrs at 37°C in a 5% CO2 atmosphere.  After incubation, the cells were per-
meabilized and washed twice with buffer (Fixation/Permeabilization kit, Becton 
Dickinson).  The cells were then stained with anti-NY-ESO-1 mAb (E978) or an 
isotype control (5 μg/ml) and FITC-conjugated mouse anti-IgG.  FcR blocking 
reagent (Miltenyi Biotec) was used for blocking nonspecific binding.  The 
stained cells were detected by FACS Calibur.  Flow cytometry results were 
analyzed with FlowJo (Tree Star, Ashland, OR). 
 
2.16. Tetramer staining 
NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer was prepared.  The me-
thod used was described previously [21].  CD4 T cells were incubated with te-
tramer for 2 hrs at 37°C in a 5% CO2 atmosphere.  FITC-conjugated anti-CD4 
mAb was added at the end of tetramer staining and incubated for an additional 
20 min at 4°C.  After incubation, the cells were washed twice and analyzed by 
FACS Calibur. 
 
2.17. Confocal microscopy 
EBV-B cells were cultured with rNY-ESO-1 protein (10 μg/ml) in a Lab-tek 
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chamber slide (Nunk, Rochester, NY) at 37°C in a 5% CO2 atmosphere for 18 
hrs.  After incubation, the cells on the slide were fixed with PFA (4%) and per-
meabilized with Triton X-100 (0.25%) (Katayama, Osaka, Japan).  The cells 
were then stained with a biotin-conjugated mouse anti-NY-ESO-1 mAb (clone 
UTK-ESO4) and FITC-conjugated streptavidin (Biomeda Corporation, Foster, 
CA).  For intracellular localization, rhodamine conjugated wheat germ aggluti-
nin (WGA) (Vector Laboratories, Burlingame, CA), PE-conjugated mouse an-
ti-CD107a (LAMP-1) mAb (EXBIO, Praha, Czech Republic) or Lysotracker Red 
DND-99 (Invitrogen Molecular Probes, Eugene, OR) were used.  The stained 
cells were visualized under a confocal microscope (LSM 510, Carl Zeiss, Jena, 
Germany).    
 
 
3. Results 
3.1. Recognition of two dominant peptide regions in NY-ESO-1 by CD4 T cells   
In a recent clinical trial, we used CHP-NY-ESO-1 to immunize patients with an 
NY-ESO-1-expressing tumor.  By analyzing responses of T cells in PBMC from 
patients using 28 18-mer overlapping peptides and a 30-mer peptide of the 
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C-terminus spanning the entire NY-ESO-1 protein (OLPs), we showed that CD4 
and CD8 T cells recognized the two dominant regions in the NY-ESO-1 molecule 
[11].  These include region 73-114 consisting of 5 peptides: 73-90, 79-96, 
85-102, 91-108 and 97-114 and region 115-144 consisting of 3 peptides: 
115-132, 121-138 and 127-144.  As shown in Fig. 1, CD4 T cells frequently 
recognized 18-mer peptides 79-96, 85-102 and 91-108 in region 73-114, and 
peptides 121-138 and 127-144 in region 115-144 in patients with different HLA 
types.  Within 11 patients shown in Fig. 1, CD4 T cell response in 3 patients was 
investigated in this study.  Patient E-2 showed strong CD4 T cell response even 
before vaccination.  Patients E-8 and P-4 showed only marginal CD4 T cell 
response before vaccination and showed marked increase after 4 vaccinations 
[11, 17].  
 
3.2. NY-ESO-1 124-134 peptide recognition by E-2 CD4 T cells restricted to 
DRB1*0803 
We determined the restriction molecule and the minimal NY-ESO-1 epitope 
recognized by E-2 CD4 T cells.  MACS bead-purified CD4 T cells from E-2 
PBMC obtained after vaccinations were stimulated in culture for 12 days with a 
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mixture of OLPs using irradiated (40 Gy), autologous CD4- and CD8-depleted 
PBMC as APC.  On the 26th day, after stimulation twice, the responding cells 
were harvested and stimulated with individual NY-ESO-1 OLPs using autologous 
CD4- and CD8-depleted PBMC as APC for 18 hrs, and assayed for IFNγ secre-
tion by ELISA for the culture supernatant.  As shown in Fig. 2A, CD4 T cells 
secreted IFNγ strongly in response to only the 18-mer peptide 121-138 (peptide 
21).  The cells were then expanded by stimulation with PHA and the restriction 
molecule for E-2 bulk CD4 T cell recognition of peptide 121-138 was determined.  
As shown in Fig. 2B, the addition of anti-HLA class II and anti-DR, but not an-
ti-HLA class I, anti-DP or anti-DQ, to the assay culture blocked IFNγ secretion.  
As shown in Fig. 2C, stimulation of E-2 bulk CD4 T cells with peptide 121-138 
using a panel of various EBV-B cells with different DR types as APC suggested 
that recognition was restricted to DRB1*0803.   
The minimal epitope peptide in the peptide 121-138 recognized by E-2 bulk 
CD4 T cells was determined using various truncated peptides that deleted N- 
and C-termini amino acids.  As shown in Fig. 2D, deletion of 5 amino acids from 
either the N- or C-terminus of peptide 121-138 greatly reduced IFNγ secretion 
from CD4 T cells.  Additional results with peptides truncated at both the N- and 
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C-termini suggested that 124-134 was the minimal epitope peptide recognized 
by E-2 bulk CD4 T cells.   
 
3.3. NY-ESO-1 95-107 peptide recognition by E-8 CD4 T cells restricted to 
DQB1*0401 
Next, we determined the restriction molecule and minimal epitope in the peptide 
91-108 in another dominant region recognized by E-8 CD4 T cells in PBMC ob-
tained after vaccinations (Fig. 1).  The response of E-8 CD4 T cells to peptide 
121-138 was likely due to the presence of DR4 on E-8 cells, which has been 
shown to present the peptide 121-130 [22] or 119-138 [23].  MACS 
bead-purified E-8 CD4 T cells were stimulated twice with peptide 91-110 using 
irradiated (40 Gy), autologous CD4- and CD8-depleted PBMC as APC.  To ob-
tain stably responding CD4 T cells, IFNγ-producing cells were cloned by limiting 
dilution in 96-well plates.  Strong IFNγ production was observed in 24/96 (25%) 
wells.  Within those, the A1 clone proliferated well and was analyzed for peptide 
recognition against individual OLPs.  As shown in Fig. 3A, E-8 A1 CD4 T cells 
recognized only the peptide 91-108 (peptide 16).  Antibody blocking and sti-
mulation of E-8 A1 CD4 T cells with peptide 91-110 using a panel of various 
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EBV-B cells with different HLA class II alleles as APC suggested that the recog-
nition was restricted to DQB1*0401 (Fig. 3B and C).  Analysis using a series of 
truncated peptides as described above suggested that the 13-mer peptide 
95-107 was the minimal epitope (Fig. 3D). 
 
3.4. Subdominant CD4 T cell response against NY-ESO-1 87-100 restricted to 
DRB1*0901 in patient P-4 who showed a dominant response against NY-ESO-1 
121-138 
We then examined whether there was any subdominant CD4 T cell response in 
patient P-4, who showed a dominant CD4 T cell response against the peptide 
121-138, using the PBMC obtained after vaccinations (Fig. 1).  The dominant 
response of P-4 CD4 T cells was explained by the presence of DRB1*1502 and 
*0901 on P-4 cells, both of which were shown to be capable of presenting epi-
topes derived from the peptide 122-138 [24]. 
MACS bead-purified P-4 CD4 T cells were stimulated twice with a mixture of 
OLPs using irradiated (40 Gy), autologous CD4- and CD8-depleted PBMC as 
APC in 96-well plates.  Cultures were then split in duplicate and stimulated with 
autologous EBV-B cells pre-pulsed with a mixture of OLPs or peptide 121-138 
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and responses were examined by IFNγ ELISA.  As shown in Fig. 4A, responses 
to both a mixture of OLPs and peptide 121-138 were observed in 7/40 (17.5%) 
wells.  However, a response to a mixture of OLPs, but not peptide 121-138, was 
observed in 3/40 (7.5%) wells.  The P-4 C3 clone reacting against a mixture of 
OLPs, but not peptide 121-138, could be expanded by PHA stimulation and its 
recognition of individual OLPs was examined.  As shown in Fig. 4B and C, P-4 
C3 cells recognized the peptide 85-102 (peptide 15) and the recognition was 
restricted to DRB1*0901.  Analysis using truncated peptides suggested that the 
minimal epitope peptide recognized by P-4 C3 CD4 T cells was 87-100 and the 
peptide was recognized at the nanomolar level (Fig. 4D).  Initial attempt for 
producing HLA class II tetramer based on the results obtained in this study was 
made for NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer.  As shown in 
Fig. 4E, P-4 C3 CD4 T cells were stained.  There was no similarity in the se-
quence between peptide 87-100 (LLEFYLAMPEATPM) defined in this study and 
peptide 122-138 (LLKEFTVSGNILTIRLT) defined previously, both of which pre-
sented on the same DRB1*0901 (Fig. 5). 
 
3.5. Natural processing of the epitope peptides 
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To examine whether the NY-ESO-1 124-134, NY-ESO-1 95-107 and NY-ESO-1 
87-100 epitopes defined in this study were naturally processed peptides, we 
examined E-2 bulk, E-8 A1 and P-4 C3 CD4 T cell recognition of EBV-B cells 
that were treated with NY-ESO-1 protein.  Treatment of EBV-B cells with re-
combinant NY-ESO-1 protein resulted in efficient endocytosis by confocal mi-
crography using anti-NY-ESO-1 mAb and WGA, LAMP-1 or Lysotracker (Fig. 
6A).  Endocytosis was blocked by addition of cytochalasin B.  Treatment of 
EBV-B cells with a complex of cholesterol-bearing hydrophobized pullulan (CHP) 
and NY-ESO-1 protein (CHP-NY-ESO-1) and NY-ESO-1 protein alone resulted 
in introduction of NY-ESO-1 protein into EBV-B cells by staining with an-
ti-NY-ESO-1 mAb after fixation (Fig. 6B).  E-2 bulk, E-8 A1 and P-4 C3 CD4 T 
cells secreted IFNγ in response to EBV-B cells introduced with NY-ESO-1 pro-
tein, but not control protein (Fig. 7A).  E-2 bulk CD4 T cell recognition of 
NY-ESO-1 protein-treated EBV-B cells was blocked by anti-DR and restricted to 
DRB1*0803 as the recognition of NY-ESO-1 124-134 peptide (data not shown). 
We further examined CD4 T cell recognition of tumor cell-derived NY-ESO-1 
antigen processed and presented by autologous EBV-B cells, or autologous or 
HLA class II-matched allogeneic DC using NY-ESO-1-expressing tumor lysates.  
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As shown in Fig 7B, E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells all recognized ly-
sate of the NY-ESO-1-expressing lung cancer cell line OU-LC-KI, but not lysate 
of control OU-LC-OK.   
 
3.6. Cytokines secreted from E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells 
Cytokines secreted from E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells in stimulation 
with peptides 121-138, 91-110, and 85-102, respectively, were examined by 
ELISA.  As shown in Fig. 7C, E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells secreted 
IFNγ and TNFα, but not IL-4 or IL-10.  The results suggested that the CD4 T 
cells induced after vaccination were the Th1-type. 
 
 
4. Discussion 
In this study, we identified 3 novel NY-ESO-1 CD4 T cell epitopes using PBMC 
obtained from patients who were immunized with CHP-NY-ESO-1.  The restric-
tion molecules were determined by antibody blocking and using various EBV-B 
cells with different HLA alleles as APC to present peptides for CD4 T cells.  The 
minimal epitope peptides were determined using various peptides truncated at 
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both the N- and C-termini that were deduced from 18-mer overlapping peptides 
originally identified for recognition.  These epitopes were NY-ESO-1 87-100 
bound to DRB1*0901, NY-ESO-1 95-107 bound to DQB1*0401 and NY-ESO-1 
124-134 bound to DRB1*0803.  The frequency of DRB1*0901 (13.76%), 
DQB1*0401 (12.98%) and DRB1*0803 (8.29%) alleles is quite high in the Jap-
anese population.  CD4 T cells used to determine these epitope peptides rec-
ognized EBV-B cells or DC that were treated with recombinant NY-ESO-1 pro-
tein or NY-ESO-1-expressing tumor cell lysate, suggesting that the epitope pep-
tides are naturally processed.  These CD4 T cells showed a cytokine profile 
with Th1 characteristics.  Furthermore, staining of corresponding CD4 T cells 
was observed with NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer which 
was produced as an initial attempt based on the findings obtained in this study.   
Recent analyses of the immune responses of patients vaccinated with 
NY-ESO-1 protein showed that most of the responses of either CD4 or CD8 T 
cells were directed against two dominant regions in the NY-ESO-1 molecule, for 
which restriction molecules have not been fully elucidated [11, 22-30].  In our 
study, the analyses were done using 18-mer NY-ESO-1 overlapping peptides 
and the two regions were region 73-114 consisting of 5 18-mer peptides: 73-90, 
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79-96, 85-102, 91-108 and 97-114 and region 115-144, consisting of 3 peptides: 
115-132, 121-138 and 127-144 [11].  CD4 T cells frequently recognized 18-mer 
peptides 79-96, 85-102 and 91-108 in region 73-114, and peptides 121-138 and 
127-144 in region 115-144 in patients with different HLA types (Fig. 1).  The 
peptide 91-108 was a region also frequently recognized by the antibody [15].  
NY-ESO-1 87-100 bound to DRB1*0901 and NY-ESO-1 95-107 bound to 
DQB1*0401 defined in this study are in region 73-114 and NY-ESO-1 124-134 
bound to DRB1*0803 is in region 115-144.  Zarour et al. [31] originally identified 
peptide 119-143 as a promiscuous HLA class II epitope that binds to multiple DR 
molecules such as DRB1*0101, DRB1*0401, DRB1*0701, DRB1*1101, 
DRB1*1501, DRB3*0101, DRB4*0101 and DRB5*0101 expressed at a high 
frequency in Caucasian population.  The shorter peptide 122-138 was shown to 
bind to DRB1*0802, DRB1*0901, DRB1*1502 and DRB1*0405/*0410, which are 
common DR alleles in the Japanese population [24].  The promiscuous peptide 
119-143 was also shown to contain multiple HLA class I epitopes that bound to 
A66, A68, Cw3 and Cw15 [32].  Recently, an immunodominant CD4 T cell re-
sponse against NY-ESO-1 119-143 (core region 123-137) presented by DR52b 
(DRB3*0202) was shown in patients vaccinated with the recombinant NY-ESO-1 
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protein with CpG in Montanide [30].  DR52b is expressed in about half of the 
Caucasian population and the response was observed in all DR52b-positive pa-
tients.  In this study, we showed that there was a subdominant response 
against peptide 87-100 in patient P-4, who showed a dominant response against 
peptide 121-138 only.  This finding further supported the two dominant anti-
genic regions in the NY-ESO-1 molecule and indicated occurrence of simulta-
neous multiple CD4 T cell responses.  The finding that a rather high frequency 
of NY-ESO-1-specific CD4 and CD8 T cells were detected in patients analyzed in 
this study is likely due to the strong immunogenicity of peptide epitopes in the 
dominant regions.  Multiple Th1-type CD4 T cell responses are very beneficial 
for inducing effective immune responses against the NY-ESO-1 antigen. 
Several clinical trials have been reported on NY-ESO-1 protein vaccination.  
Davis et al. [10] and Nicholaou et al. [33] showed that recombinant NY-ESO-1 
protein with ISCOMATRIX adjuvant efficiently induced antibodies, and both CD4 
and CD8 T cell responses in malignant melanoma patients.  Jäger et al. [14] 
reported that recombinant vaccinia and fowlpox NY-ESO-1 vaccines preferen-
tially induced a CD8 T cell response.  However, Valmori et al. [12] showed that 
vaccination with NY-ESO-1 protein and CpG in Montanide preferentially induced 
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a CD4 T cell response.  The CHP-NY-ESO-1 vaccine used in our study induced 
both CD4 and CD8 T cell responses efficiently in most patients as did the 
NY-ESO-1 ISCOMATRIX vaccine [11].  The findings that either CD4 or CD8 T 
cells responded to the two dominant regions in the NY-ESO-1 molecule sug-
gested that protein fragments or peptides including those two dominant regions 
may be substituted for NY-ESO-1 whole protein vaccine and induce efficient 
CD4 and CD8 T cell responses.  A clinical trial using NY-ESO-1 overlapping 
peptides including the two immunodominant regions is currently ongoing.   
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Figure Legends 
Fig. 1.  Patients’ HLA class II genotypes and NY-ESO-1 peptides recognized by 
CD4 T cells.  MACS bead-purified CD4 T cells (2 x 106) from patients’ PBMC 
were stimulated twice with a mixture of 28 18-mer overlapping peptides and a 
30-mer C-terminal peptide spanning the entire NY-ESO-1 protein (OLPs) (1 
μg/ml) using irradiated (40 Gy), autologous CD4- and CD8-depleted PBMC (2 x 
106) as APC.  CD4 T cells (1 x 105) from the culture were then assayed for IFNγ 
secretion using FACS Calibur after stimulation for 4 hrs with PFA-treated auto-
logous CD4- and CD8-depleted PBMC (1 x 105) pre-pulsed with individual OLPs 
(1 μM).  Each bar indicates an 18-mer NY-ESO-1 peptide to which a CD4 T cell 
response was observed.   
 
Fig. 2.  E-2 CD4 T cell recognition of the NY-ESO-1 124-134 peptide in restric-
tion to DRB1*0803.  E-2 CD4 T cells (2 x 106) obtained after CHP-NY-ESO-1 
vaccinations were stimulated twice with a mixture of OLPs (1 μg/ml) using irra-
diated (40 Gy), autologous CD4- and CD8-depleted PBMC (2 x 106) as APC.  A. 
E-2 bulk CD4 T cells (1 x 104) were then assayed for IFNγ secretion after sti-
mulation for 18 hrs with autologous EBV-B cells (1 x 104) pre-pulsed with indi-
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vidual OLPs (1 μM).  E-2 CD4 T cells recognized the peptide 21 (121-138).  B. 
Antibody blocking.  E-2 bulk CD4 T cells (1 x 104) were stimulated for 18 hrs 
with autologous EBV-B cells (1 x 104) pre-pulsed with the peptides 121-138 (1 
μM) in the presence of anti-HLA class I, anti-HLA class II, anti-HLA-DP, an-
ti-HLA-DQ or anti-HLA-DR mAb (5 μg/ml) in the culture.  C. E-2 bulk CD4 T 
cells (1 x 104) were stimulated for 18 hrs with peptide 121-138 (1 μM) using a 
panel of various EBV-B cells (1 x 104) with different HLA-DR types as APC.  D. 
E-2 bulk CD4 T cells (1 x 104) were stimulated for 18 hrs with autologous EBV-B 
cells (1 x 104) pre-pulsed with truncated NY-ESO-1 121-138 peptides.  IFNγ in 
the culture supernatants was determined by ELISA.  
 
Fig. 3.  E-8 CD4 T cell recognition of the NY-ESO-1 95-107 peptide in restriction 
to DQB1*0401.  E-8 CD4 T cells (2 x 106) obtained after CHP-NY-ESO-1 vac-
cinations were stimulated twice with the peptide 91-110 (1 μg/ml) using irra-
diated (40 Gy), autologous CD4- and CD8-depleted PBMC (2 x 106) as APC.  
Clone A1 was then established by limiting dilution.  A. E-8 A1 CD4 T cells (1 x 
104) were then assayed for IFNγ secretion after stimulation for 18 hrs with auto-
logous EBV-B cells (1 x 104) pre-pulsed with individual OLPs (1 μM).  E-8 A1 
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CD4 T cells recognized the peptide 16 (91-108).  B. Antibody blocking.  E-8 A1 
CD4 T cells (1 x 104) were stimulated for 18 hrs with autologous EBV-B cells (5 x 
103) pre-pulsed with the peptides 91-108 (1 μM) in the presence of anti-CD4, 
anti-CD8, anti-HLA class I or anti-HLA class II mAb (5 μg/ml) in the culture.  C. 
E-8 A1 CD4 T cells (1 x 104) were stimulated for 4 hrs with the peptide 91-108 (1 
μM) using a panel of various EBV-B cells (1 x 104) with different HLA class II 
types as APC.  D. E-8 A1 CD4 T cells (1 x 104) were stimulated for 18 hrs with 
autologous EBV-B cells (1 x 104) pre-pulsed with a series of 15-mer overlapping 
peptides encompassing peptide 91-110 (5 μM) (left).  Analysis with truncated 
95-107 peptides (right).  IFNγ in the culture supernatant was determined by 
ELISA in A, B and D.  In C, IFNγ-secreting CD4 T cells were determined by an 
IFNγ secretion assay using FACS Calibur.   
 
Fig .4.  P-4 CD4 T cell recognition of NY-ESO-1 87-100 peptide in restriction to 
DRB1*0901.  A. P-4 CD4 T cells (5 x 104) obtained after CHP-NY-ESO-1 vac-
cinations were stimulated twice with a mixture of OLPs using irradiated (40 Gy), 
autologous CD4- and CD8-depleted PBMC (5 x 104) as APC in 96-well 
round-bottomed culture plates.  Cultures were then split in duplicate and sti-
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mulated for 18 hrs with autologous EBV-B cells (5 x 103) pre-pulsed with a mix-
ture of OLPs or peptide 121-138 (1 μM).  Responses to both a mixture of OLPs 
and peptide 121-138 were observed in 7/40 wells (*).  Response to a mixture of 
OLPs, but not peptide 121-138, was observed in 3/40 wells (**).  B. P-4 C3 CD4 
T cells (1 x 104) were stimulated for 18 hrs with autologous EBV-B cells (1 x 104) 
pre-pulsed with individual OLPs (1 μM).  Recognition of peptide 15 (85-102) 
was observed.  C. P-4 C3 CD4 T cells (1 x 104) were stimulated for 18 hrs with 
autologous EBV-B cells (1 x 104) pre-pulsed with peptide 85-102 (1 μM) in the 
presence of anti-CD4, anti-CD8, anti-HLA class I, anti-HLA class II, anti-HLA-DP, 
anti-HLA-DQ or anti-HLA-DR mAb (5 μg/ml) in the culture in antibody blocking 
(left).  P-4 C3 CD4 T cells (1 x 104) were stimulated for 18 hrs with peptide 
85-102 (1 μM) using a panel of various EBV-B cells (1 x 104) with different 
HLA-DR types as APC (right).  D. P-4 C3 CD4 T cells (1 x 104) were stimulated 
for 18 hrs with autologous EBV-B cells (1 x 104) pre-pulsed with a series of 
18-mer overlapping peptides encompassing peptides 79-96, 85-102 and 91-108 
(125 nM) (left).  Analysis with peptide 87-100 is shown (right).  IFNγ in the 
culture supernatants was determined by ELISA.  E. P-4 C3 CD4 T cells were 
stained with NY-ESO-1 87-100 peptide / HLA-DRB1*0901 tetramer or control 
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tetramer and anti-CD4 mAb.  Analysis was performed using FACS Calibur. 
 
Fig. 5.  Amino acid sequence of NY-ESO-1 protein and HLA class II minimal 
epitope peptides identified in this study.  
 
Fig.6.  Endocytosis of NY-ESO-1 protein by EBV-B cells.  A. Fluorescence 
microscopy.  E-8 EBV-B cells were incubated with NY-ESO-1 protein (10 μg/ml) 
for 18 hrs and analyzed.  Staining was performed with anti-NY-ESO-1 mAb 
(UTK-ESO4) (green), and counter staining was performed with either wheat 
germ agglutinin (WGA), mouse anti-CD107a mAb (LAMP-1) or Lysotracker (red) 
(left).  Cytochalasin B (20 μM) was added to block endocytosis (right).  B. E-2 
EBV-B cells were cultured with CHP-NY-ESO-1 protein, NY-ESO-1 protein alone 
or CHP-MAGE protein (each 10 μg/ml) for 18 hrs and stained with mouse an-
ti-NY-ESO-1 mAb (E978) or an isotype control and FITC-conjugated mouse IgG.  
Analysis was performed using FACS Calibur.  
 
Fig. 7.  Natural processing of epitope peptides recognized by CD4 T cells and 
cytokine secretion.  Stimulation of E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells (1 x 
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104) with autologous EBV-B cells (1 x 104) treated with NY-ESO-1 protein (10 
μg/ml) (A), and with autologous EBV-B cells (1 x 104) and autologous (E-8 A1 
and P-4 C3) or HLA class II-matched allogeneic (E-2) DC treated with tumor cell 
lysates (B, top).  In A, RL-Akt protein (10 μg/ml) was used as control protein.  
In B, bottom, RT-PCR analysis for expression of NY-ESO-1 mRNA in tumor cell 
lines, OU-LC-KI and OU-LC-OK is shown.  GAPDH was used for the internal 
control.  C. E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells were stimulated for 18 hrs 
with autologous EBV-B cells (1 x 104) pre-pulsed with the respective cognate 
peptides.  IFNγ, TNFα, IL-4 and IL-10 in the culture supernatants were detected 
by ELISA. 
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